12 Review of baseline symptoms. Abbreviated Title: mRNA-Based, Cancer Vaccine Version Date: January 23, 2019 32 Assessments Screening (Prior to Part Two registration) Baseline (Prior to first vaccine) On-Study/Course of Treatment (1 vaccine = 1 cycle)1 Post-Treatment Follow-up Within 3 Months Within 4 Weeks Within 7 Days Within 7 Days Within 2 Days Day 0 Day 14 (±5 d) Day 28 (±5 d) Day 42 (±5 d) Day 562 (±5 d) Subsequent Follow-up Visits3 HIV antibody titer, HBsAg, anti- HCV X Anti-CMV antibody titer, HSV and VZV, EBV panel 13 X Laboratory Procedures CBC w/differential X X X X X X X Blood chemistries14 X X X X X X X PT-INR/PTT X Lymphocyte phenotyping (TBNK) X X X X Additional apheresis15 X Correlatives16 CPT tubes (SB-CPF) X X X X X X SST tubes (Figg Lab) X X X X X X Imaging CT, MRI, PET, and/or photography X17 X18 X19 X19 Chest x-ray X Treatment/Intervention NCI-4650 mRNA vaccine20 X X X X 13 Patients who are known to be positive do not need to be retested. May be performed within 3 months prior to Part Two registr ation.